PMID- 11975700
OWN - NLM
STAT- MEDLINE
DCOM- 20020910
LR  - 20191025
IS  - 0269-4727 (Print)
IS  - 0269-4727 (Linking)
VI  - 27
IP  - 2
DP  - 2002 Apr
TI  - Penetration of levofloxacin into skin tissue after oral administration of 
      multiple 750 mg once-daily doses.
PG  - 143-50
AB  - OBJECTIVE: To probe the pharmacokinetic basis for the use of levofloxacin for 
      complicated skin and skin-structure infections (SSSIs) at a once-daily dosage of 
      750 mg by investigating its penetration into skin tissue. METHOD: Ten healthy 
      volunteers were administered three oral, once-daily 750 mg doses of levofloxacin, 
      and levofloxacin concentrations were subsequently measured over time (0.5-24 h) 
      in skin-punch biopsy tissue and plasma. RESULTS: Skin tissue concentrations 
      consistently exceeded those in plasma at every time point, with tissue/plasma 
      ratios of 1.37 +/- 0.81 for peak concentration and 1.97 +/- 0.35 for area under 
      the concentration versus time curve. Three of the ten subjects reported 
      treatment-emergent adverse events (AEs) that were considered unrelated to 
      treatment. An 11th subject who had enrolled in the study withdrew after AEs of 
      mild severity that were possibly related to the study drug. CONCLUSION: The 
      results support the clinical usage of levofloxacin 750 mg once-daily for 
      complicated SSSIs.
FAU - Chow, A T
AU  - Chow AT
AD  - Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ 
      08869-0602, USA. achow@prdus.jnj.com
FAU - Chen, A
AU  - Chen A
FAU - Lattime, H
AU  - Lattime H
FAU - Morgan, N
AU  - Morgan N
FAU - Wong, F
AU  - Wong F
FAU - Fowler, C
AU  - Fowler C
FAU - Williams, R R
AU  - Williams RR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Infective Agents)
RN  - 6GNT3Y5LMF (Levofloxacin)
RN  - A4P49JAZ9H (Ofloxacin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Anti-Infective Agents/administration & dosage/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - *Levofloxacin
MH  - Male
MH  - Middle Aged
MH  - Ofloxacin/administration & dosage/*pharmacokinetics
MH  - Skin/chemistry
MH  - Skin Diseases/*drug therapy
MH  - Tissue Distribution
EDAT- 2002/04/27 10:00
MHDA- 2002/09/11 10:01
CRDT- 2002/04/27 10:00
PHST- 2002/04/27 10:00 [pubmed]
PHST- 2002/09/11 10:01 [medline]
PHST- 2002/04/27 10:00 [entrez]
AID - 396 [pii]
AID - 10.1046/j.1365-2710.2002.00396.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2002 Apr;27(2):143-50. doi: 10.1046/j.1365-2710.2002.00396.x.